GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Common Stock

TECX (Tectonic Therapeutic) Common Stock : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Common Stock?

Tectonic Therapeutic's quarterly common stock stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) and stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Tectonic Therapeutic's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).


Tectonic Therapeutic Common Stock Historical Data

The historical data trend for Tectonic Therapeutic's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Common Stock Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Common Stock
- - - -

Tectonic Therapeutic Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only - - - - -

Tectonic Therapeutic Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Tectonic Therapeutic Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.